Antimutagenic effect of phenethyl isothiocyanate

Petr Smerák1, Zdenka Polívková, Rudolf Stetina

  • 1Charles University in Prague, 3rd Faculty of Medicine, Department of General Biology and Genetics, Prague, Czech Republic. smerak@gmail.com

Insights

Phenethyl isothiocyanate (PEITC) demonstrated antimutagenic effects against aflatoxin B1 (AFB1), 2-amino-3-methylimidazo[4,5-f]quinoline (IQ), and N-nitroso-N-methylurea (MNU) in bacterial and mammalian cell tests. PEITC also reduced mutagenicity in vivo, suggesting a role in preventing carcinogenesis.

Area of Science:

  • Toxicology
  • Chemoprevention
  • Molecular Biology

Background:

  • Mutagens like aflatoxin B1 (AFB1), 2-amino-3-methylimidazo[4,5-f]quinoline (IQ), and N-nitroso-N-methylurea (MNU) pose significant health risks.
  • Chemoprotective agents are crucial for mitigating mutagenic and carcinogenic effects.
  • Phenethyl isothiocyanate (PEITC) is a substance with potential chemoprotective properties.

Purpose of the Study:

  • To evaluate the antimutagenic activity of PEITC against indirect and direct-acting mutagens.
  • To assess the efficacy of PEITC in preventing DNA damage induced by mutagens.
  • To investigate the chemopreventive potential of PEITC in vivo.

Main Methods:

  • Ames bacterial mutagenicity test using S. typhimurium TA98 and TA100 strains.
  • Comet assay on HepG2 cells to detect DNA breaks.
  • In vivo micronucleus test in mice.
  • Exposure to AFB1, IQ, and MNU as mutagens.

Main Results:

  • PEITC dose-dependently reduced AFB1 and IQ mutagenicity in the Ames test.
  • PEITC showed antimutagenic effects against MNU in the Ames test at higher concentrations.
  • PEITC significantly decreased MNU-induced DNA breaks in HepG2 cells but not IQ-induced breaks.
  • PEITC administration in mice significantly reduced micronucleus formation caused by all tested mutagens.

Conclusions:

  • PEITC exhibits significant antimutagenic properties against a range of mutagens.
  • PEITC demonstrates chemopreventive effects by reducing DNA damage and mutagenicity.
  • PEITC's antimutagenic activity suggests a potential role in preventing carcinogenesis and related diseases.

Related Concept Videos

Mutagenicity and Carcinogenicity01:25

Mutagenicity and Carcinogenicity

Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
Bioactivation and Tissue Toxicity01:25

Bioactivation and Tissue Toxicity

Bioactivation is a metabolic process that transforms less reactive substances into highly reactive metabolites, initiating tissue toxicity. This transformation can lead to various toxic effects, including carcinogenesis and teratogenesis. Reactive metabolites are classified into two main types: electrophiles and free radicals.Electrophiles are electron-deficient species and are produced primarily by the enzyme cytochrome P-450 during the metabolism of compounds containing carbon, nitrogen, or...
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
Drug toxicity: Idiosyncratic Reactions01:16

Drug toxicity: Idiosyncratic Reactions

Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...
Cancer Prevention02:59

Cancer Prevention

Several factors can increase the risk of cancer in an individual. About 50% of cancer cases can be prevented by adopting a healthy lifestyle, regular exercise, eating healthy, and following a modest cancer prevention diet. Epidemiological studies have consistently shown that populations with vegetable and fruit-rich diets have reduced the incidence of cancer. On the other hand, populations who have a diet rich in animal fat, red meat, junk food, or high calories are predisposed to cancer.
Some...